Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma.

被引：5

作者：

Mehmi, Inderjit ^{[1
,2
]}

Hill, Jordan ^{[1
,2
]}

机构：

[1] WVU Med, WVU Canc Inst, Morgantown, WV USA

[2] WVU Canc Inst WVU Med, Morgantown, WV USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.e21552

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e21552

引用

页数：1

共 50 条

[41] Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Hepner, A.
Carlino, M. S.
Johnson, D. B.
Gerard, C. L.
Lo, S.
Pallan, L.
Silva, I. D.
Michielin, O. A.
Long, G. V.
Menzies, A. M.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[42] A Case of Pembrolizumab (Anti-PD-1) Induced Encephalitis
Zahid, Anza
Poursheykhi, Meryim
Saeed, Mujtaba
Tremont, Ivo
[J]. NEUROLOGY, 2022, 99 (23) : S72 - S73
[43] Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Joanna Baginska
Allison Nau
Ilana Gomez Diaz
Anita Giobbie-Hurder
Jason Weirather
Juliana Vergara
Charlotte Abrecht
Margaret Hallisey
Jenna Dennis
Mariano Severgnini
Julia Huezo
Isabella Marciello
Osama Rahma
Michael Manos
Andrew S. Brohl
Philippe L. Bedard
Daniel J. Renouf
Elad Sharon
Howard Streicher
Patrick A. Ott
Elizabeth I. Buchbinder
F. Stephen Hodi
[J]. Cancer Immunology, Immunotherapy, 2024, 73
[44] Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Baginska, Joanna
Nau, Allison
Gomez Diaz, Ilana
Giobbie-Hurder, Anita
Weirather, Jason
Vergara, Juliana
Abrecht, Charlotte
Hallisey, Margaret
Dennis, Jenna
Severgnini, Mariano
Huezo, Julia
Marciello, Isabella
Rahma, Osama
Manos, Michael
Brohl, Andrew S.
Bedard, Philippe L.
Renouf, Daniel J.
Sharon, Elad
Streicher, Howard
Ott, Patrick A.
Buchbinder, Elizabeth I.
Hodi, F. Stephen
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (01)
[45] Efficacy of combined hypofractionated radiotherapy and anti-PD-1 monotherapy in patients with melanoma.
Roger, Anissa
Finet, Adeline
Boru, Blandine
Mazeron, Jean-Jacques
Otmezguine, Yves
Blom, Astrid
Longvert, Christine
De Maleissye, Marie-Florence
Beauchet, Alain
Saiag, Philippe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[46] Anti-PD-1 therapy in the frontline
David Killock
[J]. Nature Reviews Clinical Oncology, 2016, 13 (12) : 715 - 715
[47] Proteomic profiling to predict therapeutic response to anti-PD-1 therapy in advanced melanoma
Zila, N.
Levesque, M.
Paulitschke, V.
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 37 - 37
[48] First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland
Cybulska-Stopa, Bozena
Pacholczak-Madej, Renata
Kaminska-Winciorek, Grazyna
Zietek, Marcin
Czarnecka, Anna M.
Piejko, Karolina
Galus, Lukasz
Ziolkowska, Barbara
Kieszko, Stanislaw
Kempa-Kaminska, Natasza
Calik, Jacek
Rolski, Janusz
Salek-Zan, Agata
Gajewska-Wicher, Katarzyna
Drosik-Kwasniewska, Anna
Rogala, Pawel
Kubiatowski, Tomasz
Suwinski, Rafal
Mackiewicz, Jacek
Rutkowski, Piotr
[J]. IMMUNOTHERAPY, 2021, 13 (04) : 297 - U32
[49] Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma
Zhao, Lingdi
Yang, Yonghao
Ma, Baozhen
Li, Wei
Li, Tiepeng
Han, Lu
Zhang, Yong
Shang, Yi-Man
Lin, Hongwei
Gao, Quanli
[J]. JOURNAL OF ONCOLOGY, 2019, 2019
[50] Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan
Harada, Kentaro
Yamamoto, Shun
Kato, Ken
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (11) : 1333 - 1338

← 1 2 3 4 5 →